The COG SDC is responsible for all statistical and data operations within the COG. It also supports many of theadministrative activities of the COG. The IT support required for all statistical and data center operations is alsoprovided by the SDC grant.
The specific aims of the SDC are to: 1. Collaborate on the development of the COG's scientific agenda, as full members of Disease and Modality Committees 2. Provide leadership in the design of COG research, collaborating on the development of study pre-concepts, concepts, and protocols and providing study statistical considerations, includingsample size calculations and interim monitoringplans 3. Collaborate on the development of study case report forms used to collect the minimal data required for the evaluation of the study aims 4. Maintain a centralized remote data entry system to collect study data from COG institutions,resource centers, and reference laboratories, and maintainquality control procedures to assure the accuracy of COG research data 5. Monitor study data submitted by participating COG institutions,monitor the timeliness of data submissionand provide institutionswith expectancy and delinquencyreports, review submitted data, coordinate the collection and review of materials collected for modality reviews (pathology, surgery, radiation therapy), and coordinate study committee review of study data 6. Monitor study conduct, includingaccrual, patient safety, and study outcome; prepare public protocol progress reports for the COG and confidential reports of interim outcome data for the COG's Data Monitoring Committees 7. Collaborate on the production of abstracts and manuscripts reporting the results of COG science 8. Conduct research on statistical methods that have direct relevance to COG's research goals and conduct special analyses (e.g., on prognostic factors, outcome for specific patient subsets, etc.), taking advantage of the wealth of information contained in the group's research databases 9. Provide statistical collaboration for the COG's correlative laboratory research agenda. 10. Collaborate with members of the Group Operations Center in the completion of various administrative activities, including institutional audits and institutional performance monitoring 11. Provide education and training to the Group membership, including collaboration on the trainingof new study chairs, collaboration on new and continuingeducation training for institutionalclinical research associates and presentations on statistical issues of interest to the Group membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
7U10CA098413-12
Application #
8914171
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
2003-06-20
Project End
2015-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
12
Fiscal Year
2014
Total Cost
$246,268
Indirect Cost
$14,706
Name
University of Florida
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
DuBois, Steven G; Krailo, Mark D; Gebhardt, Mark C et al. (2015) Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer 121:467-75
Buitenkamp, Trudy D; Izraeli, Shai; Zimmermann, Martin et al. (2014) Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123:70-7
McCune, Jeannine S; Bemer, Meagan J; Barrett, Jeffrey S et al. (2014) Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res 20:754-63
Myers, Regina M; Balsamo, Lyn; Lu, Xiaomin et al. (2014) A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Cancer 120:1417-25
Schultz, K R; Devidas, M; Bowman, W P et al. (2014) Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. Leukemia 28:964-7
Walterhouse, David O; Pappo, Alberto S; Meza, Jane L et al. (2014) Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology J Clin Oncol 32:3547-52
Schultz, K R; Carroll, A; Heerema, N A et al. (2014) Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 28:1467-71
Mansour, Marc R; Abraham, Brian J; Anders, Lars et al. (2014) Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346:1373-7
Libes, Jaime M; Seeley, Erin H; Li, Ming et al. (2014) Race disparities in peptide profiles of North American and Kenyan Wilms tumor specimens. J Am Coll Surg 218:707-20
Morgenstern, Daniel A; London, Wendy B; Stephens, Derek et al. (2014) Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol 32:1228-35

Showing the most recent 10 out of 222 publications